Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
6,778 total articles
ProQR Therapeutics announced the nomination of Dr. Lykke Hinsch Gylvin, Chief Medical Officer at Boehringer Ingelheim, to its Board of Directors. Dr. Hinsch Gylvin brings extensive experience in global drug development across multiple therapeutic areas. Her appointment is expected to support ProQR's continued advancement of its proprietary Axiomer …
Emergent BioSolutions has received approval from the Singapore Health Sciences Authority for an expanded indication of its ACAM2000 vaccine to include prevention of mpox disease in adults at high risk. This milestone broadens the vaccine's authorized use to support public health preparedness against mpox outbreaks in Singapore, reinforcing Emergent…
MoneyHero Limited, a Nasdaq-listed fintech company operating in Southeast Asia, announced its unaudited Q4 and audited full year 2025 results, highlighting a significant turnaround with the first quarterly net profit of $0.5 million and an Adjusted EBITDA gain of $0.7 million. The company achieved revenue growth driven by higher-margin products lik…
Aebi Schmidt Holding AG, a global leader in specialty vehicles, will release its first quarter 2026 financial results before market open on May 14, 2026. The company will also hold a webcast and live conference call for investors and analysts. Headquartered in Switzerland and listed on NASDAQ, Aebi Schmidt operates across Europe and North America, …
CCC Intelligent Solutions Holdings Inc. announced that CFO Brian Herb will depart in May 2026, with Rodney Christo stepping in as interim CFO. The company also reported strong Q1 2026 financial results, with 12% revenue growth and 21% adjusted EBITDA growth compared to Q1 2025, reinforcing its growth trajectory in the insurance technology sector.
Roadzen Inc. (Nasdaq: RDZN) announced a non-binding Letter of Intent with a leading U.S. commercial insurance carrier to secure $30 million in underwriting capacity for a new commercial auto insurance program, expected to scale to $50 million over three years. Backed by over $50 million in committed premium demand from its U.S. producer network, th…
Parker Hannifin Corporation reported strong fiscal 2026 third quarter results, with record sales of $5.5 billion, up 11% year-over-year. Adjusted net income and EPS rose 16% and 18% respectively, driven by solid organic sales growth, strong order rates, and improved segment operating margins. The company increased its full-year guidance, expecting …
Yuanbao Inc., a Nasdaq-listed technology-driven online insurance distributor in China, announced the filing of its annual report on Form 20-F for fiscal year 2025 with the U.S. Securities and Exchange Commission. The report includes audited consolidated financial statements and is accessible via the company's investor relations website. Yuanbao ser…
FTI Consulting announced first quarter 2026 financial results featuring a 9.5% increase in revenues to $983.3 million and a 9.2% increase in EPS to $1.90 compared to the prior year quarter. Despite higher revenues, net income declined due to increased costs, higher SG&A expenses, interest expense, and a higher tax rate. The company reaffirmed its f…
Palvella Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel therapies for rare skin diseases and vascular malformations, will report its Q1 2026 financial results on May 7, 2026. The company will hold a conference call to discuss the results and corporate update. Palvella's lead products are investigational therapi…
TG Therapeutics, a commercial-stage biotechnology company focusing on B-cell disease treatments, announced a conference call on May 6, 2026, to discuss first quarter financial results and provide a business update for the remainder of 2026. The company recently obtained FDA approval for BRIUMVI for treating relapsing multiple sclerosis and continue…
Helus Pharma announced that Interim CEO Eric So will participate in a panel on health innovation at the 29th Annual Milken Institute Global Conference. The company is developing novel serotonergic agonists (NSAs) for mental health conditions including major depressive disorder and generalized anxiety disorder, with some products in advanced clinica…
Saia, Inc. reported first quarter 2026 financial results with revenue rising 2.4% to $806.2 million, while diluted EPS remained flat at $1.86 compared to Q1 2025. Operating income decreased 4.8%, reflecting a slightly higher operating ratio and lower LTL tonnage per workday despite increased shipments. The company continues investing in its nationa…
Hubbell Incorporated reported robust first quarter 2026 financial results with 11% net sales growth (8.2% organic), 16% increase in adjusted EPS to $3.93, and improved operating margins. The company raised its full-year 2026 diluted EPS guidance, anticipating strong sales and profit growth driven by key segments such as Electrical Solutions and Uti…
Laureate Education, Inc. reported first quarter 2026 financial results with new enrollments up 9% and total enrollments up 6%, revenue increasing 15% on a reported basis (1% constant currency). Operating loss widened due to academic calendar timing and higher expenses related to campus expansion projects. The company completed $105 million in share…
DT Midstream reported strong financial results for Q1 2026 with net income of $130 million and Adjusted EBITDA of $308 million. The company declared a $0.88 per share dividend and approved investments in key pipeline expansion projects including the Vector Pipeline 2028 expansion and Millennium Pipeline R2R project. These developments position DT M…
Barinthus Biotherapeutics disclosed its Q1 2026 financials showing reduced net loss and solid cash position. The company is advancing a transformative merger with Clywedog Therapeutics to create a differentiated pipeline focused on metabolic and autoimmune diseases. Clinical development of their lead asset VTP-1000 in celiac disease is progressing …
Dragonfly Energy Holdings Corp. (Nasdaq: DFLI), a leader in lithium battery manufacturing and energy storage solutions, announced it will release its first quarter 2026 financial and operational results on May 14, 2026 after market close. The earnings release will be followed by a conference call and webcast for investors and interested parties.
SIGA Technologies, a commercial-stage pharmaceutical company specializing in treatments and prevention of infectious diseases, announced a webcast and conference call on May 7, 2026, to discuss its first-quarter 2026 financial results and provide a business update. CEO Diem Nguyen and CFO Daniel Luckshire will participate in the call, which will be…
BridgeBio Pharma, a biopharmaceutical company specializing in medicines for genetic conditions, announced it will report its Q1 2026 financial results and provide commercial updates after market close on May 7, 2026, followed by a conference call. The webcast will be accessible via the company's investor website.
Alterity Therapeutics reported significant progress for its lead drug candidate ATH434 in treating Multiple System Atrophy (MSA), including positive FDA Type C meeting feedback supporting Phase 3 trial design and presentation of Phase 2 data demonstrating consistent efficacy in slowing disease progression. The company appointed experienced leadersh…
FTAI Infrastructure Inc. announced the definitive agreement to sell its Long Ridge Energy & Power assets to MARA Holdings, Inc. for approximately $1.52 billion. The transaction will eliminate $1.16 billion of Long Ridge debt and allow FIP to repay an estimated $300 million of its parent-level debt and reinvest in new growth opportunities, including…
AC Immune SA, a biopharmaceutical company specializing in precision therapeutics for neurodegenerative diseases, announced key updates from its Q1 2026 financial report and clinical pipeline progress. The company initiated dosing in a Phase 1 trial for ACI-19764 (NLRP3 inhibitor), started a final cohort in the Phase 1b/2 trial for ACI-24 targeting …
Option Care Health, the largest independent home and alternate site infusion services provider, announced Q1 2026 financials showing modest revenue growth but slight declines in net income and adjusted EBITDA. The company expressed concerns about revenue momentum and outlined plans to accelerate growth. Updated full-year 2026 guidance includes expe…
uniQure announced a successful pre-submission meeting with the UK MHRA regarding its gene therapy AMT-130 for Huntington's disease and plans to submit a Marketing Authorization Application in Q3 2026. The company also has a Type B meeting scheduled with the US FDA to discuss Phase III trial design. AMT-130 showed a 75% slowing of disease progressio…
